Isaac Kinde, M.D., Ph.D.
Chief Scientific Officer
PapGene Inc., launched in 2014 out of the Johns Hopkins University system and now is commercializing novel “genetic cytology” technologies for the improved management of cancer patients.
“Our unique approach allows for the detection of a variety of cancers at early stages when patients have the highest chance of being cured of their disease with therapies available today,” Isaac Kinde, M.D., Ph.D., said.
The idea, he said, is that all cancers are caused by genetic defects that can be exploited for their detection.
Traditional cancer detection methods, he said, often are more invasive and ineffective.
While Kinde said the approach developed by PapGene Inc., can be applied more broadly, the focus now is on ovarian cancer screening.
Kinde has been honored as a Forbes 30 Under 30 in science and health care in 2013 and was named a Game Changer by Men’s Fitness in 2014.
“Our goal is to improve the outcome of cancer patients by identifying patients with early-stage curable disease,” Kinde said. “We are now developing the laboratory infrastructure and conducting the clinical studies required before our tests can be offered to patients.”